These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 38195521

  • 21. Valproic acid concentration and biochemical indexes in epilepsy outpatients during monotherapy or combination therapy.
    Yang X, Wang P, Pan J, Wang C, Luo J, Ma H.
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2020 Jul 28; 45(7):782-789. PubMed ID: 32879081
    [Abstract] [Full Text] [Related]

  • 22. Determination of Free Valproic Acid Concentration in 569 Clinical Samples by LC-MS/MS After Hollow Fiber Centrifugal Ultrafiltration Treatment.
    Wu X, Li H, Dong W, Yang X, Jin Y, Gong Y, Zhang Z, Liu X.
    Ther Drug Monit; 2021 Dec 01; 43(6):789-796. PubMed ID: 33990504
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Impact of Age and Genotype on Serum Concentrations of Valproic Acid and Its Hepatotoxic Metabolites in Chinese Pediatric Patients With Epilepsy.
    Zhao M, Chen Y, Wang M, Li G, Zhao L.
    Ther Drug Monit; 2020 Oct 01; 42(5):760-765. PubMed ID: 32107351
    [Abstract] [Full Text] [Related]

  • 25. The relationship between glucuronide conjugate levels and hepatotoxicity after oral administration of valproic acid.
    Lee MS, Lee YJ, Kim BJ, Shin KJ, Chung BC, Baek DJ, Jung BH.
    Arch Pharm Res; 2009 Jul 01; 32(7):1029-35. PubMed ID: 19641884
    [Abstract] [Full Text] [Related]

  • 26. Effect of valproate dose on formation of hepatotoxic metabolites.
    Anderson GD, Acheampong AA, Wilensky AJ, Levy RH.
    Epilepsia; 1992 Jul 01; 33(4):736-42. PubMed ID: 1628592
    [Abstract] [Full Text] [Related]

  • 27. Potential relationships between transaminase abnormality and valproic acid clearance or serum carnitine concentrations in Japanese epileptic patients.
    Goto S, Seo T, Hagiwara T, Ueda K, Yamauchi T, Nagata S, Ando Y, Ishitsu T, Nakagawa K.
    J Pharm Pharmacol; 2008 Feb 01; 60(2):267-72. PubMed ID: 18237476
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Determination of the Optimal Concentration of Valproic Acid in Patients with Epilepsy: A Population Pharmacokinetic-Pharmacodynamic Analysis.
    Nakashima H, Oniki K, Nishimura M, Ogusu N, Shimomasuda M, Ono T, Matsuda K, Yasui-Furukori N, Nakagawa K, Ishitsu T, Saruwatari J.
    PLoS One; 2015 Feb 01; 10(10):e0141266. PubMed ID: 26484865
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. [The decreased level of plasma carnitine in patients with epilepsy].
    Belousova ED.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017 Feb 01; 117(6):106-110. PubMed ID: 28745680
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Valproic acid-induced nocturnal enuresis in pediatric patients.
    Ozan K, Coskun Y, Bora CK, Ayten Y.
    Niger J Clin Pract; 2019 Jan 01; 22(1):108-112. PubMed ID: 30666028
    [Abstract] [Full Text] [Related]

  • 35. Safety range of free valproic acid serum concentration in adult patients.
    Tseng YJ, Huang SY, Kuo CH, Wang CY, Wang KC, Wu CC.
    PLoS One; 2020 Jan 01; 15(9):e0238201. PubMed ID: 32877431
    [Abstract] [Full Text] [Related]

  • 36. The influence of old age and enzyme inducing comedication on the pharmacokinetics of valproic acid at steady-state: A case-matched evaluation based on therapeutic drug monitoring data.
    Fattore C, Messina S, Battino D, Croci D, Mamoli D, Perucca E.
    Epilepsy Res; 2006 Aug 01; 70(2-3):153-60. PubMed ID: 16730950
    [Abstract] [Full Text] [Related]

  • 37. Valproate metabolites in high-dose valproate plus phenytoin therapy.
    Sugimoto T, Muro H, Woo M, Nishida N, Murakami K.
    Epilepsia; 1996 Dec 01; 37(12):1200-3. PubMed ID: 8956852
    [Abstract] [Full Text] [Related]

  • 38. Association of LEPR and ANKK1 Gene Polymorphisms with Weight Gain in Epilepsy Patients Receiving Valproic Acid.
    Li H, Wang X, Zhou Y, Ni G, Su Q, Chen Z, Chen Z, Li J, Chen X, Hou X, Xie W, Xin S, Zhou L, Huang M.
    Int J Neuropsychopharmacol; 2015 Mar 03; 18(7):pyv021. PubMed ID: 25740917
    [Abstract] [Full Text] [Related]

  • 39. Relationship between valproic acid dosage, plasma concentration and clearance in adult monotherapy patients with epilepsy.
    Gidal BE, Pitterle ME, Spencer NW, Maly MM.
    J Clin Pharm Ther; 1995 Aug 03; 20(4):215-9. PubMed ID: 8557785
    [Abstract] [Full Text] [Related]

  • 40. Factors Influencing Sodium Valproate Serum Concentrations in Patients with Epilepsy Based on Logistic Regression Analysis.
    Lan X, Mo K, Nong L, He Y, Sun Y.
    Med Sci Monit; 2021 Nov 15; 27():e934275. PubMed ID: 34776507
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.